What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
The Outperformers (91-100)
These companies have been ranked based on their stock's excess return over the Sensex for a five-year period
September 10, 2019
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Sailesh Raj Bhan has made optimum use of cyclical downturns to deliver outperformance
Khushboo Balani - January 25, 2018
Is the worst over for pharma stocks?
The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
July 17, 2017
Oh No! Aurobindo
The recent negative news flow has led to a selling spree in Aurobindo Pharma
Jash Kriplani - January 24, 2017
Aurobindo Pharma promoters sell over 10 million shares in a market transaction valued at Rs.900 crore
Jitendra Kumar Gupta - October 14, 2016
Hyderabad’s pharma players are adapting to a regulatory backlash and fighting back against dumping from China
Krishna Gopalan - March 09, 2016
Overdosing on growth
A shift in focus in the US and the EU has propelled the stock price of Aurobindo Pharma to an all-time high
Adit Mathai - April 20, 2015